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Introduction and Objective: Dengue virus is a serious global health problem with an
estimated 3.97 billion people at risk for infection worldwide. In December 2015, the first
vaccine (CYD-TDV) for dengue prevention was approved in Brazil, developed by Sanofi
Pasteur. However, given that the vaccine will potentially be paid via the public health
system, information is need regarding consumers’ willingness to pay for the dengue
vaccine in the country as well as discussions related to the possible inclusion of this
vaccine into the public health system. This was the objective of this research.
Methods: We conducted a cross-sectional study with residents of Greater Belo
Horizonte, Minas Gerais, about their willingness to pay for the CYD-TDV vaccine.
Results: 507 individuals were interviewed. These were mostly female (62.4%) had
completed high school (62.17%), were working (74.4%), had private health insurance
(64.5%) and did not have dengue (67.4%). The maximum median value of consumers’
willingness to pay for CYD-TDV vaccine is US$33.61 (120.00BRL) for the complete
schedule and US$11.20 (40.00BRL) per dose. At the price determined by the Brazil’s
regulatory chamber of pharmaceutical products market for the commercialization of
Dengvaxia©R for three doses, only 17% of the population expressed willingness to pay
for this vaccine.
Conclusion: Brazil is currently one of the largest markets for dengue vaccine and the
price established is a key issue. We believe the manufacturer should asses the possibility
of lower prices to reach a larger audience among the Brazilian population.
Keywords: dengue, willingness to pay, vaccine, consumers, Brazil
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INTRODUCTION
Dengue is an arbovirosis transmitted to humans by the bite of
a mosquito of the Aedes genus, especially, Aedes aegypti. It is
estimated that 390 million infections occur annually worldwide
(Gubler, 2011; Bhatt et al., 2013), with the number of cases of
dengue increasing in frequency and geographic region (Guzman
et al., 2010; Brady et al., 2012; Simmons et al., 2012; Bhatt
et al., 2013). Based on mathematical modeling, the global annual
incidence has been estimated at approximately 50 to 100 million
symptomatic cases each year in recent years (Beatty et al., 2011;
Bhatt et al., 2013). This flavivirus represents an important social
and economic impact in most tropical and subtropical countries,
and it is currently estimated that approximately US$5million are
spent annually on hospitalizations related to dengue worldwide
(Suaya et al., 2009). However, this is now likely to be a
considerable under-estimate.
Dengue is endemic in Brazil, with a high and increasing
incidence in recent years (Brasil, 2011, 2013, 2016). In 2015,
there were 1,587,080 registered cases probably due to dengue, 839
deaths and an incidence of 782.6 cases /100,000 inhabitants. In
the State of Minas Gerais, there was a demonstrated incidence
of 879.8 cases/100,000 inhabitants and 67 deaths (Brasil, 2016).
Data released by the National Information System of Notifiable
Diseases (SINAN) demonstrated the occurrence of 2,320,956
and 4,406,767 cases of dengue in the state of Minas Gerais and
Brazil respectively between 2010 to 2014 (Brasil, 2014a). In 2014,
more than 150 million Brazilian reais (US$42.016million) were
spent on surveillance, prevention and control of dengue and
chikungunya virus in Brazil (Brasil, 2014b).
Until now, there has not been a specific licensed treatment
for dengue, and the development of effective vaccines against
all four serotypes of DENV is an important strategy to control
this flavivirus and significantly contribute to reducing the disease
burden (Webster et al., 2009; Durbin and Whitehead, 2011;
McArthur et al., 2013). Common strategies to help control
dengue include preventing mosquitoes from accessing egg-
larving habitats, using environmental management interventions
such as removing artificial man-made mosquito habitats,
emptying and cleaning domestic water storage containers, as
well as personal and household protection including applying
insecticides (Brasil, 2002; World Health Organization [WHO],
2016).
Recently, the tetravalent chimeric vaccine CYD-TDV from
Sanofi Pasteur was approved for the prevention of dengue
in endemic countries including Mexico, the Philippines, El
Salvador, Costa Rica, Paraguay and Brazil (Brasil, 2015a,b;
Dengue Vaccine Initiative [DVI], 2015; Roland and Bisserbe,
2015). The disappointing results in individuals under 9 years of
age (Hadinegoro et al., 2015) led to vaccine being indicated for the
population 9 years or older. The resultant approved indication
from this first dengue vaccine is for individuals 9–45 years (e.g.,
Brazil) or 9–60 years of age (e.g., Paraguay), depending on the
license (World Health Organization [WHO], 2016).
CYD-TDV was evaluated during the active phase of
surveillance (25 months post-enrolment) in CYD14 (Capeding
et al., 2014) and CYD15 (Villar et al., 2015). As per the protocol,
vaccine efficacy against virologically confirmed symptomatic
dengue illness was 56.5% (95% CI; 43.8% – 66.4%) in CYD14,
assessed in Asia, and CYD15 with 60.8% (95% CI; 52% – 68%)
evaluated in clinical trials conducted in Latin America including
Brazil. Sanofi Pasteur recommended the administration of three
doses each 6 months apart (World Health Organization [WHO],
2016). However, the complete duration of vaccine protection
is still unknown (Hadinegoro et al., 2015; World Health
Organization [WHO], 2016).
The Brazil’s regulatory chamber of the pharmaceutical
products market (CMED) is responsible for evaluating and
establishing the prices of medicines for commercialization in
Brazil by Resolution n◦2 of 5 March 2004, referencing prices
for the same medicines in other countries including Australia,
Canada, and the United States (Brasil, 2004). From prices
established by CMED, pharmaceutical companies may apply for
incorporation of their products into the national health system
by sending a process submission to the National Commission
on Technology Incorporation of the National Health System
(CONITEC) (Brasil, 2008). In this context, endemic countries,
including Brazil, will have to make important decisions such
as the possible incorporation of this vaccine into their public
systems within a context of constrained budgets. In this scenario,
pharmacoeconomic evaluations, such as the assessment of
willingness-to-pay and cost-effectiveness analysis, are important
for decision-making (Palanca-Tan, 2008; Lee et al., 2015).
Willingness-to-pay (WTP) is a relevant methodological
approach to estimate the maximum amount that an individual is
willing to allocate to programs, services and health technologies.
It is usually applied in cost-benefit analysis and in health
technology assessment (Haab and Mcconnell, 2002). The lack of
available WTP studies with the Brazilian consumer for a dengue
vaccine, and the possible upcoming vaccination with CYD-TDV
in the country, is a concern given the potential budget impact
and the current economy situation. This study sought to estimate
the Brazilian consumers’ willingness to pay for this vaccine in
order to contribute to the debate and pharmacoeconomic reviews
focusing on demand and potential prices for dengue treatments
in Brazil.
MATERIALS AND METHODS
This study estimated the willingness to pay of Brazilian
consumers toward the CYD-TDV dengue vaccine through an
analysis of contingent valuation, which enables evaluation of
the monetary amount an individual is willing to pay to acquire
a certain product or service using questionnaires with direct
questions. The respondents did not have the disease at the time
of the interview, but they may or may not have had dengue in the
past (Haab and Mcconnell, 2002).
Design and Study Location
The survey was conducted in the metropolitan region of Belo
Horizonte, capital of Minas Gerais State, the second most
populous state in Brazil. Minas Gerais state has 21,013,869
inhabitants with 2,375,151 inhabitants currently registered in the
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Belo Horizonte metropolitan region. In addition, Belo Horizonte
and Brazil presented, respectively, a mean Human Developed
Index of 0.810 and 0.737 in 2010 (Atlas do Desenvolvimento
Humano no Brasil, 2016).
Minas Gerais State is similar to Brazil as a whole for
certain aspects including mean income per capita and socio
demographics. Mean income per capita was US$315.97
(1128.00BRL) for Brazil and US$311.76 (1113.00BRL) per month
for Minas Gerais in 2015 (Instituto Brasileiro de Geografia e
Estatística [IBGE], 2014; Agência Brasil, 2016). In addition,
despite that there being 26 States in the country, Minas Gerais
has one sixth of the Brazilian cities and represents a relevant
epidemiological context for the flavivirus (Brasil, 2014a, 2016).
In addition in 2013, Minas Gerais was the State with the
highest number of dengue cases in the country (Brasil, 2014a).
Consequently, providing a robust sample for the study.
Participants were interviewed using a questionnaire developed
by the research team, based on a literature review (Haab and
Mcconnell, 2002; Palanca-Tan, 2008; Lee et al., 2015). The
survey was conducted in May 2016 and the interviewers were
undertaken by graduate and undergraduate students of the
School of Pharmacy of the Federal University of Minas Gerais,
trained to conduct interviews and answer possible questions.
Data Collection Instrument
The technique for measuring the willingness to pay is the
application of a questionnaire, with prior presentation to the
respondent of all the features of the disease and the intervention
necessary for decision-making, as well as the involved conditions
and important aspects of the clinical context of the disease. To
fully implement this technique, it is essential that all participants
have received the same information. This was assured by specific
and intensive training of the interviewers (Haab and Mcconnell,
2002).
The questionnaire was divided in five sections: (1) Questions
to understand what the participants knew about dengue; (2)
Information about the disease, intervention and alternatives for
disease prevention; (3) Questions to test the understanding of the
information provided; and (4) Discrete Choice, Bidding Game
and Open-Ended questions (Haab and Mcconnell, 2002). Section
5 consisted of a self-reported socioeconomic questionnaire. The
questions in section (4) were included in order to assess whether
individuals would be willing to pay US$54.05 (180.00 BRL) for
the three-dose scheme of CYD-TDV vaccine as well as obtain
an estimate of a range of values and a point estimate that
respondents would pay for the technology.
US$54.05 for three doses of CYD-TDV for the Discrete Choice
technique was established based on the maximum price for the
consumer of the yellow fever vaccine – US$19.50 (64.92BRL)
(Fiocruz Laboratory), established by CMED in 20 July 2016
(Agência Nacional de Vigilância Sanitária [ANVISA], 2016).
All questions related to the research context and/or difficulties
in completing the socioeconomic questionnaire were clarified
by the interviewers. The information about the mean effective
protection for all four serotypes (∼60%), as well as the possibility
of local (e.g., swelling at the site of application and pain) and
systemic (e.g., fever, myalgia, asthenia, and headache) adverse
events were included in the text read to all participants in the
initial stage of the interview. There was also a figure explaining
graphically the efficacy of the vaccine to aid the dissemination of
information.
Sampling and Selection Criteria
Interview selection was random. Passers by in major circulation
paths, close to parks, markets and fairs in the metropolitan region
of Belo Horizonte were invited to participate and, if they agreed,
answered the questionnaire in the same location. Considering
the scenario with higher uncertainty that is 50% respondents
agreeing to pay the value of US$54.05 (180.00BRL), with a
two-sided 0.05 significance, we calculated a minimum of 400
respondents would be required in this research.
Individuals could or not have history of dengue, but could not
presently have symptoms or have a diagnosis of the disease at
the time of the interview. To be selected, individuals must have
declared that they have an income. Individuals under 18 without
their own income were excluded. In addition, participants who
showed willingness to pay higher than twice the value of their
declared monthly income and individuals who would not use this
vaccine, even if it would be free, were excluded from the analysis
in line with previous publications (Lee et al., 2015).
Data Analysis
The willingness to pay for dengue vaccine was estimated by the
median of the maximum declared value by the individuals who
were willing to pay any amount greater than or equal to zero.
The median among groups defined by covariates were compared
using the Mann-Whitney test (two groups) or Kruskal–Wallis
test (three or more groups). The significance level was 5%. All
socioeconomic variables were evaluated and the relation with
the maximum value of willingness to pay for CYD-TDV, such as
education and income were included. To assess income variation,
we stratified the value of “<3”; “3–10” and “>10” times the
minimum wage, in order to measure the percentage of individuals
for each range.
Furthermore, we measured the frequency of the participants
that have or not private health insurance. According to the
National Regulatory Agency for Private Health Insurance and
Plans (ANS), that regulates the private health insurances in
Brazil, Minas Gerais has coverage of private health insurance of
between 20 and 30%, with 5,467,559 beneficiaries in the State
in 2014. The coverage in Brazil was 25.2% of the population
(48,824,150 individuals) in March 2016 (Agência Nacional de
Saúde Suplementar [ANS], 2016a,b).
In addition, we further evaluated the relation of willingness
to pay by individuals that had previously had or not dengue.
Statistical analysis was performed using Microsoft Excel 2007, R
(R Core Team, 2014) and Minitab 17. For comparison purposes,
we adopted the conversion value established by the World Bank
for Purchasing Power Parities (PPPs) (2015: 1 US$1= 3.330BRL).
Ethics Statement
All interviews were conducted after reading and signing the
Term of Free and Clarified Consent. All researchers of the
project signed a confidentiality agreement prior to the interviews.
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This study was approved by the Ethics Committee of the
Federal University of Minas Gerais (COEP) under the CAAE
57219816.0.0000.5149.
RESULTS
Population Characteristics
We conducted 507 interviews with individuals aged between
18 and 84 years old who agreed to participate and answer
the questionnaire. The mean age of respondents was
34.6 ± 12.8 years, 37.6% were male, 74.4% were working at
the time of interview, and 37.8% had completed higher education
(Table 1).
The participants who reported a history of dengue were 32.6%,
the utilization of public health service was reported by 49.3%,
and those respondents who reported at least one dengue case in
the household were 43.8%. In approximately 70% of respondents,
their family income was below five times the minimum wage
(Table 1).
Willingness to Pay for CYD-TDV Dengue
Vaccine
Of the 507 subjects, 7.3% said they would not be vaccinated
even if CYD-TDV did not have any cost. The main reasons for
this were efficacy (37.8%) and safety (40.5%). In addition, only
three (8.1%) respondents said they did not use any vaccines and
59 (11.6%) said they would use this vaccine only if it would be
provided free of charge. Considering these exclusions criteria, 464
respondents were eligible for the WTP analysis.
Among these 464 individuals, 37.9% were men, 88.8% had
completed high school or more, 39.2% had children, 73.7% were
working at the moment of interview, 62.1% had health insurance
and 31.7% had previously had dengue. The participants who
reported a family income up to 10 times the minimal wage were
83.4% (Figure 1).
With the application of the Discrete Choice Technique, it was
found that 44% of participants were willing to pay US$54.05
(180.00BRL) for the three-dose regimen of the vaccine. Of the 190
respondents who had children, 131 (68.9%) were willing to pay
USD$54.05 for CYD-TDV vaccination of their family. Results of
the Bidding Game technique revealed that, in general, the amount
the respondents were willing to pay ranged from US$27.03
(90.00BRL) to US$108.11 (360.00BRL), representing 54.1% of
individuals involved in interview. The minimum and maximum
willingness to pay for three doses of CYD-TDV vaccine were of
0.00 and 1,800.00 BRL.
The willingness to pay for dengue vaccine by the Brazilian
consumer was estimated at the median value of US$36.04
(120.00BRL) for the three-dose regimen or US$12.01 (40.00BRL)
per dose. This means that 50% of individuals interviewed
reported maximum values of willingness to pay equal to or less
than US$36.04 (Figure 2).
The only variable correlated with willingness to pay with
statistical significance (<0.05) was monthly income (p = 0.003)
when stratified as “<3,” “3–10” and “>10” times the minimum
wage, representing family income values under US$739.50
TABLE 1 | Characteristics of the respondents.
Variable n (%)∗∗
Age in years [mean (SD)] 34.6 12.5%
Men 188 37.6%
Has children 197 (38.9%)
Educational level
Had never attended school 2 0.4%
Complete primary education 46 9.3%
Completed high school 261 52.5%
Complete college or more 188 37.8%
Currently working 372 74.4%
Have health insurance 318 64.5%
Dengue history 162 32.6%
Had dengue and reported having used only the
public health system
68 49.3%
Had dengue and reported having used only a
private health provider
54 39.1%
Had dengue and reported have used both
services
16 11.6%
Reported that other people in the household
had dengue
212 43.8%
Family income (number of minimal wages)∗
<1 8.5%
1–2 15.4%
2–3 15.2%
3–5 20.7%
5–10 22.5%
10–20 7.9%
>20 1.2%
∗8.6% of respondents refused to answer on family income. ∗∗The value of the
difference to reach 100% in all questions, are due to answers such as “I do not
know” and “I do not want to answer.”
FIGURE 1 | Family income of respondents included in analysis of the
willingness to pay for dengue vaccine (CYD-TDV) in this study. ∗NA,
not available – The respondents that answered, “I do not know and I do not
want to answer”; mw, minimal wage.
(2,640.00BRL) (30.8%), between US$792.79 (2,640.00BRL) and
US$2,642.64 (8,800.00BRL) (34.1%) and above US$2,642.64
(6.9%), respectively, per month. Median values of willingness
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FIGURE 2 | Cumulative percentage of individuals willing to pay for CYD-TDV vaccine according to the maximum values reported.
to pay for these three groups were respectively US$30.03
(100.00BRL) and US$54.05 (180.00BRL) for the highest income
groups (Figure 3). As expected, the increase of family income
contributed to a higher willingness to pay, which is logical
and consistent with the published theory (Haab and Mcconnell,
2002).
DISCUSSION
This study sought to estimate the willingness to pay among
Brazilian consumers for the dengue vaccine recently licensed
in the country, with the study population having similarities
with the profile of the Brazilian population as a whole. This
included certain characteristics such as higher percentage of
women (51.4%), a low percentage of individuals who have
never studied (8.5%) and the percentage of individuals with
at least 11 years of education (41.8%) (Instituto Brasileiro de
Geografia e Estatística [IBGE], 2014). The percentage of families
in our study with income less than 5 times the minimum
wage was just under 70% (Table 1). This value was below the
Brazilian Institute of Geography and Statistics (IBGE) in their
profiling family in the national context, where the percentage
was 87.9%. This might contribute for a higher median value
of willingness to pay for the vaccine compared to the national
population (Instituto Brasileiro de Geografia e Estatística [IBGE],
2014).
In this study, the percentage of respondents who reported
having health insurance was 64.5% (Agência Nacional de Saúde
Suplementar [ANS], 2016b). The Brazilian private market for
health insurance is strictly regulated by the National Regulatory
Agency for Private Health Insurance and Plans, which works
on behalf of the Ministry of Health. Private health insurance
can either be purchased individually or obtained as a work
benefit, depending on the employer. The Brazilians that decide to
purchase private health insurance may still access public health
services if they wish or need. The Brazilian public health system,
named SUS, was established in 1988 by constitution in order
to guarantee access to health care to the entire population.
The public system maintains primary and outpatient centers,
hospitals, diagnostic laboratories and should provide access
to pharmaceuticals including vaccines (Rizzotto and Campos,
2016).
The median willingness to pay value for CYD-TDV was
US$33.61 (120.00/11.20BRL dose) for the three-dose scheme
and clinical efficacy of 60% (Hadinegoro et al., 2015; Godói
et al., 2016). The reason for expressing values in medians in
willingness to pay analysis (Palanca-Tan, 2008; Hadisoemarto and
Castro, 2013; Lee et al., 2015) is that the mean is sensitive to
outliers, which may contribute to an erroneous perception of
what the population is indeed willing to pay. The median value
of US$33.61 shows the maximum amount 50% of respondents
would be willing to pay; however, this does not represent an
estimated average number of people willing to pay for the vaccine
(Buckland and Macmillan, 1999).
This study is the first study in Brazil to consider the
actual scenario of a possible vaccination with CYD-TDV
with clinical information arising from clinical phase III
trials (Capeding et al., 2014; Villar et al., 2015) and from
the 25 months follow-up study (Hadinegoro et al., 2015).
Other studies adopted a hypothetical vaccination scenario
with 100% safety and efficacy and with protection for
10 years and for life, as seen, respectively, in the studies
conducted in the Philippines (Palanca-Tan, 2008) and Indonesia
(Hadisoemarto and Castro, 2013). However, we believe
this is an unrealistic scenario given the current clinical
information.
The number of doses used in the studies was also variable.
A single dose study was conducted in the Philippines (Palanca-
Tan, 2008) and Indonesia (Hadisoemarto and Castro, 2013) and
three doses in Vietnam, Thailand and Colombia (Lee et al., 2015),
which is similar to our study. Among the respondents in our
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FIGURE 3 | Box plot of the willingness to pay for three doses of CYD-TDV according to family income. NB. The results were statistically significant (<0.05);
(∗) Extreme values presented for each income range; mw, minimal wage.
study, 7.3% reported not wishing to be vaccinated even if the
vaccine was free of charge. The same situation happened in the
studies from Vietnam, Thailand, and Colombia (Lee et al., 2015).
The willingness to pay of Brazilian consumers of US$33.61
(BRL120.00) is closer to that observed in endemic countries such
as Vietnam and Colombia. This is between the values found
in Vietnam at US$26.13 and the Philippines at US$60.00. The
observed values in Indonesia, Colombia, and Thailand and were
respectively US$ 1.94, US$22.60 and US$ 69.78. The studies
published in the context of willingness to pay for dengue, in
general, considered a hypothetical dengue vaccine with results of
efficacy, safety and protection time better than the results seen
with CYD-TDV in phase III clinical trials (Palanca-Tan, 2008;
Hadisoemarto and Castro, 2013; Lee et al., 2015). Consequently,
again questioning the findings.
The Brazil’s regulatory chamber of pharmaceutical products
market is an inter-ministerial body responsible for price setting.
New-patented innovative products such as Dengvaxia R© are
classified as Class I. As a result, manufacturer prices may not
exceed the lowest price in the following markets: Australia,
Canada, France, Greece, Italy, New Zealand, Portugal, Spain,
or United States of America (Brasil, 2004). However, since
CYD-TDV is not marketed in these countries, CMED had no
comparison to establish a price for vaccine in Brazil. On July 25th
of 2016, CMED reported that the manufacturer price for each
Dengvaxia R© dose in Brazil may vary from US$37.19 to US$38.80
(132.76–138.53BRL) according to the States (provinces) tax rates
of each of the 26 states of Brazil. For Minas Gerais State, the
maximum consumer price is US$37.71 (134.63BRL). Considering
the need for three doses of the vaccine to achieve planned efficacy,
the amount paid for each person vaccinated will be at least
US$113.13 (403.89BRL), which represents the willingness to pay
of only 17% of the population in this study.
Mahoney et al. (2012) studying the production costs of
another dengue vaccine, which is being developed at the Butantan
Institute, found that the production scale (15 million doses per
year) in ten vials should cost around US$0.51 to US$0.65 per
vial. When the quantity produced increases to 60 million doses
per year, the cost of production could potentially fall to US$0.20
per dose. The authors demonstrated that vaccines for Japanese
encephalitis and type A meningitis are available in developing
countries at prices below US$1.00 per dose. This is much lower
than consumer prices demanded by manufacturer in Brazil or
established by CMED.
Brazil has a comprehensive immunization program with
coverage for an appreciable number of infections. In future
scenarios, we believe public health systems purchasing the
dengue vaccine should assess carefully the cost-effectiveness ratio
in combination with a budget impact analysis, as the efficacy
of this new dengue vaccine may be considered insufficient
compared to other vaccines for similar conditions or disease
burden with appreciably lower prices. Comparisons with other
vaccines prices and effectiveness for diseases with similar burden
may contribute to political decisions regarding the possibility
of incorporating this technology into public health systems at
acceptable and reasonable prices, bearing in mind the current
economic climate in Brazil and the desire to continue to offer
universal healthcare. Such discussions have grown in recent times
driven by the increasing prices for new medicines especially new
cancer medicines and those for orphan diseases, despite costs
of research and production estimated at US$50 to 100 million
per compound by some authors (Experts in Chronic Myeloid
Leukemia, 2013; Phelan and Cook, 2014; Godman et al., 2015;
Howard et al., 2015; Tefferi et al., 2015; Bruijn et al., 2016).
In a study conducted in Brazil, Araújo et al. (2016) estimated
the potential impact of vaccination against dengue. In a more
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conservative scenario, the authors estimated a 22% reduction
in cases of dengue (routinely vaccinate up to 9 years old and
vaccination campaign up to 10 years) and 81% in the liberal
scenario (routine to 9 years and vaccination campaign up to
40 years) over 5 years. Furthermore, they demonstrated that
vaccination could reduce 233,000 hospitalizations due to the
disease during the considered period. CYD-TDV was licensed
for individuals with age between 9 and 45 years old (Brasil,
2015a). However, it is important to balance this against the
potential budget impact. This especially as it is important to
emphasize that all efforts and strategies for vector control by
governments and society will need to continue since the vaccine
has only 60% efficacy, and especially because of other existing
arboviruses, such as Chikungunya and Zika (Tilak et al., 2016),
with Zika related to microcephaly epidemics in Brazil (Brasil,
2015b).
The contingent valuation is the most common approach
to estimate the monetary value for goods and services from
hypothetical questions (Haab and Mcconnell, 2002; Palanca-
Tan, 2008; Hadisoemarto and Castro, 2013; Lee et al., 2015).
However, some limitations are noted such as the respondents
may not have full information (e.g., disease, severity and
frequency of symptoms) or that it may simulate a scenario
very distinct and different compared with the real situation
(e.g., efficacy of the intervention). To avoid such limitations,
the questionnaire used must be complete and up to date and
include all relevant situations and conditions related to the
intervention or service in the analysis to avoid possible bias
(Boyle, 2003). This study was conducted using efficacy results
extracted from the analysis of 27,355 individuals from 2 to
16 years old (Hadinegoro et al., 2015). These results were used
to grant commercial license to Dengvaxia R© for children as
well as adults in Brazil and in other countries (Godói et al.,
2016). Consequently, helping to address such concerns. Real-
world results of the vaccine are currently missing, which may
overestimate the value of the WTP (if effectiveness is lower),
or underestimate the value (if effectiveness is higher – most
unlikely scenario). In addition, the respondent’s willingness
to pay were constrained within the attributes and levels
presented in this study. Lastly, the random sample used
may not be fully generalizable to population of Brazil as
a whole. However, despite these limitations, we believe our
findings do provide guidance to the Brazilian authorities and
the manufacturers of the vaccine on potential pricing and
reimbursement strategies.
CONCLUSION
Despite the limitations regarding income differences between
citizens in Minas Gerais and Brazil as a whole as well as
limitations with the sampling method, we believe this study
provides important information about how much consumers are
willing to pay for the CYD-TDV vaccine approved in Brazil
to avoid the risk of being infected. From the price determined
by CMED for commercialization of Dengvaxia R© (Minas Gerais),
i.e., US$113.13 for three doses, only 17% of the participants
involved in this study were willing to pay for this vaccine, and
this from a higher income base than Brazil as a whole. This is
a concern given the current resource constrained environment
in Brazil. We believe, based on our study findings, that the
manufacturers may wish to reconsider their pricing strategy.
This is because Brazil constitutes one of the largest markets for
dengue vaccine and there are appreciable competing demands
on available resources, especially given the current economic
situation in Brazil.
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